GSK

Science unites against disease

London, United Kingdom

GSK plc is a British multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and commercialization of prescription medicines and vaccines. Formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since demerged its consumer healthcare business to focus exclusively on biopharmaceuticals, with its global headquarters in London, England.

Shareable draft

Check out GSK on @MedStartr Today GSK plc is a British multinational pharmaceutical and biotechnology company specializing in the research, development, manufacturing, and commercialization of prescription medicines and vaccines. Formed in 2000 from the merger of Glaxo Wellcome and SmithKline Beecham, GSK has since demerged its consumer healthcare business to focus exclusively on biopharmaceuticals, with its global headquarters in London, England. #RespiratoryDiseases #ImmunologicalDiseases #InflammatoryDiseases #HIVAIDS #MentalBehavioralHealth #InfectiousDiseases #CancerOncology #DrugDiscoveryDevelopment #MedMo #MedStartrVentures

https://www.medstartr.ai/s/IGBRBWR-xNk

Note, this image was autogenerated by Syggy based on what we know about the company. It is not an official company publication.

Get Involved in GSK

How We Help

Problem Statement

To address various diseases and health challenges by discovering, developing, and delivering innovative medicines and vaccines across critical therapeutic areas.

Core Technology

R&D strategy and pipeline centered on four core therapeutic areas, leveraging understanding of inflammatory mechanisms and the immune system.

Key Differentiators

Leader in HIV research with an industry-leading pipeline, broadest infectious diseases portfolio in the industry, and a recent strategic focus exclusively on biopharmaceuticals after demerging its consumer healthcare business.

Clinical Focus

Respiratory, immunology, and inflammation; Oncology; HIV; Infectious diseases.

Target Customers

Healthcare providers, patients (via prescription)

Product Stage

Mature

Company Info

Business Model: B2B
Founded: 2000
Website: gsk.com

Disease Areas

Respiratory Diseases Immunological Diseases Inflammatory Diseases HIV/AIDS Mental Health Infectious Diseases Cancer & Oncology

Technologies

RNA Therapeutics ResearchOpen-Source ModelsDrug DiscoveryVaccine DevelopmentImmunologyInflammatory MechanismsBiotechnology

Clinical & IP

🔬

Clinical Validation

13 phase III readouts in 2024. FDA approvals 2024-2025: Exdensur (severe asthma), RSV vaccine Arexvy (expanded indication), Penmenvy (5-in-1 meningococcal), Blujepa (first-in-class UTI antibiotic), Blenrep (multiple myeloma), Nucala (COPD). Pipeline: 69 compounds total, 18 in phase III/registration.

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of GSK?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.